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Editorial on Research Topic
Should We Treat Aging as a Disease? Academic, Pharmaceutical, Healthcare Policy, and
Pension Fund Perspectives
The quest to increase healthy lifespan is becoming a pressing economic priority required to preserve
the current standards of living. Rapidly increasing dependency ratios and unfunded social security
and healthcare liabilities are an enormous and growing burden on the economies of developed
countries (Zhavoronkov et al., 2012; Zhavoronkov, 2013). But the situation, if handled properly, is
not hopeless; with advances in anti-aging treatments and preventative care, the negative economic
impact of aging could be at very least reduced, while increases in productive longevity in developed
countries could actually stimulate significant economic growth (Zhavoronkov and Litovchenko,
2013).
One of the impediments to industry transformation is the way aging is treated. While no doubt
exists that aging is a complex multifactorial process leading to a progressive decline in function
with no single cause or treatment (Zhavoronkov and Cantor, 2011; Moskalev et al., 2014), the issue
of whether aging can be classified as a disease is widely debated by gerontologists, medical doctors,
demographers, philosophers, policy makers, and the general public. This disagreement has until
now hindered classification of aging as a disease and, consequently, the fitting of potential treatment
options into established research, regulatory, insurance, and marketing frameworks.
By initiating a call for papers via a research topic with a descriptive “Should we Treat Aging
as a Disease? Academic, pharmaceutical, healthcare policy, and pension fund perspectives” title in
Frontiers in Genetics, we gathered the opinions of the many stakeholders including representatives
of the pharmaceutical and biotechnology industries, demographers, and research scientists. None
of the representatives of the pensions fund and insurance industries queried responded to the
call, which can be explained by the general attitude toward aging and longevity in these industries
(Zhavoronkov, 2015).
Some of the prominent biogerontologists provided comprehensive weighted responses
explaining the dangers of separation of aging from disease and benefits of proactive preventative
approaches that are likely to result from recognizing the pathological nature of aging. In spite of
the many breakthroughs providing proof of concept for successful interventions in aging in model
organisms, human progress has been surprisingly slow. One major cause of inaction is a widely
held, but flawed, conceptual framework concerning the relationship between aging and disease that
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categorizes the former as “natural” and the latter as “abnormal”
(Faragher). Gems concluded a comprehensive review of themany
arguments for and against classifying aging as a disease with a
definite and eloquent recommendation that calls for a complete
quote: “We must draw aside the rosy veil of tradition and face
aging for what it is, and in all its horror: the greatest disease of
them all” (Gems).
Bulterijs et al. explained the many benefits of classifying
aging a disease (Bulterijs), while Stambler provided a historical
perspective arguing that acknowledging the possibility of
successful intervention into the aging process, in other words
treating aging as a curable disease, has been a long and
highly respected tradition of biomedical thought (Stambler).
Dubnikov and Cohen provided an overview of multiple theories
of aging and recommended further research to understand the
relationship between aging and disease (Dubnikov and Cohen).
Vaiserman proposed taking a systems-oriented approach
looking at the plurality of genetic pathways and epigenetic
mechanisms for identifying aging-modulating interventions
(Vaiserman) complementing the signalome-wide approach for
geroprotector screening (Zhavoronkov et al.). Zarling et al.,
proposed using nitroxide agents as possible drugs targeting
age-related macular degeneration and other age-related diseases
(Zarling et al.), and Luo et al. proposed a healthcare economics-
driven model for development and adoption of companion
diagnostics (Luo et al.).
Advocates for longevity research provided new survey data
indicating that the majority (74.4%) of Americans are interested
to live to 120 or longer if health was guaranteed, but only 57.4%
wished to live that long if it wasn’t (Donner et al.), contradicting
previous surveys that used different approaches to surveying
the general population and generally indicated negative attitudes
toward increased longevity and longevity-boosting interventions
(Duncan, 2012; Pew Research Center, 2013).
Many age-related diseases and genetic disorders share
common pathways with normal aging (Tacutu et al., 2011;
Makarev et al., 2014; Aliper et al., 2015). There is evidence
indicating that longevity can be extended with a variety relatively
non-toxic interventions (Moskalev et al., 2015) and there are
multiple promising treatments in the pipeline. However, while
there are many scientists and organizations providing arguments
for and outlining the many economic and societal benefits of
recognizing aging as a disease, there are few proposals describing
concrete steps toward classifying aging as a disease. Moreover,
many arguments lack realization that aging in the form of senility
and senescence is already classified as a disease by some of the
most influential agencies.
The main international agency responsible for disease
classification is the World Health Organization (WHO),
which maintains and publishes the International Statistical
Classification of Diseases and Related Health Problems (ICD)
since 1948. The 10th revision of the ICD, referred as ICD-10,
was first published in 1992 (World Health Organization, 1992),
and the 11th revision (ICD-11) is expected to be released in 2018
(http://www.who.int/classifications/icd/revision/timeline/en/).
WHO classifies aging as a disease in the ICD-10 with the
“R54” code (World Health Organization, 1992). However, this
code is generally regarded by the Global Burden of Disease
(GBD) statisticians as a “garbage code” (Murray and Lopez,
1996; Lozano et al., 2013) and cannot be considered to be
actionable. Actionable classification of aging as a disease may
lead to more efficient allocation of resources by enabling
funding bodies and other stakeholders to use quality-adjusted
life years (QALYs) and healthy-years equivalent (HYE) as
metrics when evaluating both research and clinical programs.
In order to classify aging with an actionable code or set of
codes linked to specific age-related diseases, authors propose
an international task force to be organized to develop and
communicate proposals to the WHO at the national and
international levels (Zhavoronkov and Bhullar). We propose
starting with reclassification of age-related muscle wasting or
sarcopenia as a treatable medical condition, considering the
number of interventions developed within the pharmaceutical
industry and academia.
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